News
Jason Yi '01, an assistant professor of neuroscience at WashU Medicine, has received a $400,000 pilot grant from the Eagles ...
A mum in Monmouth describes her fears about managing her severely disabled son's care needs.
The plan comes just ahead of the presentation of detailed data from the phase 1/2 HALOS study ION582 – also known as BIIB121 – at the 2024 Angelman Syndrome Foundation (ASF) family conference ...
GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...
Clinical Trials Arena on MSN6d
Ionis doses first subject in Phase III trial of Angelman syndrome therapyIonis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at treating individuals with Angelman syndrome (AS), a rare ...
The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback